Rocketman,

You have some catching up to do, especially for someone who claims to be in the Esperion camp. The injectable apo-AI milano (ETC-216) Esperion drug that you refer to is not the orally available ATP citrate lysase inhibitor (ETC-1002; bempedoic acid). Pfizer bought Esperion back in 2003. Clinical development of ETC-216 didn't work out so well. 

https://blogs.sciencemag.org/pipeline/archives/2016/11/16/the-long-saga-of-apo-a1-milano

Wikipedia has a brief history for Esperion (https://en.wikipedia.org/wiki/Esperion_Therapeutics)

"Pfizer acquired the original Esperion in 2004 for US$1,300,000,000 as a defensive move to prevent ETC-216 from falling into competitors' hands.[2]:165 Two years later, in 2006, Pfizer decided to kill the Esperion organization and development of ETC-216. In May 2008, Dr. Roger Newton, Esperion's founder and chief scientific officer, raised sufficient capital to acquire rights to ETC-1002 and Esperion from Pfizer, thereby leading to a second independent period for the company.[2]:165[3][4] In June 2013, Esperion became a public company again through an initial public offering.[5] As of April 2014, Esperion was traded on NASDAQ under the symbol "ESPR".[6]"

ETC-1002 (bempedoic acid) has been stellar in clinical development, proving to be consistently safe and effective on its own as well as in combo with ezetimibe, statins, ezetimibe+statins, and PCSK9s. It has passed numerous Phase 2 and Phase 3 trials with flying colors. That is the reason for the valuation difference. It has NDA and MAAs pending approval with the FDA and EMA. Expected approval Q1 2020, as in the next 1.5 months! The CVOT is ongoing, so bempedoic acid will have to wait for the cardio label. But it is almost guaranteed to be approved Q1 2020 for LDL-C lowering.

BDAZ